A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.

Nasu, R; Nannya, Y; Kurokawa, M

Nasu, R; Nannya, Y; Kurokawa, M.

Affiliation

Nasu R; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Int J Hematol ; 101(4): 376-85, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25644148

Subject(s)

Antiemetics/therapeutic use; Hematologic Neoplasms/drug therapy; Morpholines/therapeutic use; Neurokinin-1 Receptor Antagonists/therapeutic use; Adult; Aged; Antiemetics/administration & dosage; Antineoplastic Agents/therapeutic use; Aprepitant; Female; Humans; Male; Middle Aged; Morpholines/administration & dosage; Morpholines/adverse effects; Nausea/chemically induced; Nausea/prevention & control; Neurokinin-1 Receptor Antagonists/administration & dosage; Neurokinin-1 Receptor Antagonists/adverse effects; Vomiting/chemically induced; Vomiting/prevention & control

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Morpholines / Hematologic Neoplasms / Neurokinin-1 Receptor Antagonists / Antiemetics Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2015 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google